Clarify Remdesivir and Convalescent Plasma Use for COVID-19
You'll hear buzz about emergency use authorizations (EUAs) for remdesivir and convalescent plasma to treat COVID-19.
Remdesivir (Veklury). FDA is expanding the EUA to include ALL hospitalized patients with suspected or confirmed COVID-19.
But there currently isn't enough evidence to be certain of a benefit in nonsevere patients...and a 5-day course costs over $3,000.